News Room

Shanghai FTZ Fund invests in Ark Biosciences, an innovative R&D enterprise of antiviral drugs

2020-08-05

Recently, Shanghai FTZ Fund has invested in ARK Biosciences (ARKbio), an innovative R&D enterprise of antiviral drugs. ARKbio is committed to the R&D of innovative antiviral drugs and pediatric drugs. In 2019, the company successfully completed a global phase II clinical study (VICTOR). This study confirmed for the first time in history that an antiviral drug has therapeutic efficacy for RSV infection in hospitalized infants and can bring clinical benefits to the children.

SHFTZFUND won multiple awards including ‘PEAS Best Investment Institution’ in 2023.

Shanghai FTZ Fund successfully holds the "Lingang Industry Salon" for Spatial Information Industry

This activity is a brand series of activities held by Shanghai FTZ Fund and its Lingang Special Area Sci-tech Innovation Fund on a regular basis.

Shanghai FTZ Fund receives China Bridge 2023 Annual Awards

Lately, Shanghai FTZ Fund has been awarded China Bridge "2023 Top 50 Private Equity Investment Institutions in China" and "2023 Best Chinese Capital Investment Institution".

Shanghai FTZ Fund awarded ZERO2IPO 2023 "Chinese State-owned Capital Investment Institutions Top50"

Today, ZERO2IPO published "China Venture Capital & Private Equity Annual Ranking 2023", and Shanghai FTZ Fund has been awarded 2023 "Chinese State-owned Capital Investment Institutions Top50"

Shanghai FTZ Fund
Wechat Official Account